Clinical trials: Symptoms, Behavioral
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
- Trial name
- NCT06786624
- Testing
- NBI-1065845
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Neurocrine Biosciences
Mental Health Issue, Depression
Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders
US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants complete a survey upon enrollment and are randomized into one of two study arms.
- Conditions
- Mental Health Issue, Depression, Anxiety
- Trial name
- NCT06502717
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Viome
Epilepsy, Major Depressive Disorder (MDD)
Lethargic Depression Study
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
- Trial name
- NCT00064467
- Testing
- Extended-release bupropion (HCl)
- Where
- 24 sites in United States
- Volunteers
- 268 people
- Sponsor
- GlaxoSmithKline
Depression
Multiple Ascending Dose Study of NH102 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as multiple oral dose at escalating dose levels in healthy participants.
- Trial name
- NCT07324408
- Testing
- NH102
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jiangsu Nhwa Pharmaceutical Co., Ltd.
Periodontal Diseases, Chronic Periodontitis
Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome
The purpose of this study was to demonstrate in patients with generalized chronic periodontitis that switching from cigarette smoking to using IQOS improves the response to periodontal therapy and the overall oral health status…
- Conditions
- Periodontal Diseases, Chronic Periodontitis, Periodontal Pocket, Tooth Mobility
- Trial name
- NCT03364751
- Testing
- IQOS, Cigarette
- Where
- 26 sites in Japan
- Volunteers
- 179 people
- Sponsor
- Philip Morris Products S.A.
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients
To assess the efficacy of Vortioxetine (5 mg daily) versus placebo in the acute treatment of depression by means of the change from baseline in the 24-item Hamilton Depression Scale (HAM-D24) total score after 8 weeks of…
- Trial name
- NCT00811252
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
- Trial name
- APPROACH (NCT06564818)
- Testing
- CYB003, Psychological Support
- Where
- 45 sites in United States
- Volunteers
- 223 people
- Sponsor
- Cybin IRL Limited
Alzheimer's Disease
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
- Trial name
- ALPO (NCT01324518)
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Orion Corporation, Orion Pharma
Delirium in the Intensive Care Unit, Burnout, Healthcare Workers
A Study of Silent Alarm Delivery Versus Standard Audible Alarm Delivery in Intensive Care and High Dependency Units
The goal of the trial is to learn if a strategy to eliminate audible alarm noise in intensive care and high dependency units can reduce overall noise levels, patient delirium, staff alarm fatigue, and staff burnout.
- Conditions
- Delirium in the Intensive Care Unit, Burnout, Healthcare Workers, Noise in the ICU, Alarm Fatigue
- Trial name
- DECIBEL (NCT07364097)
- Testing
- Silent alarm strategy
- Where
- India
- Volunteers
- 311 people
- Sponsor
- MindWave Medical Inc
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Depression
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode
Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram + Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score measured by the Hamilton Scale (HAM-D).
- Trial name
- LABCATTCJUSS (NCT02532660)
- Testing
- Escitalopram 10mg, LABCAT TCJUSS
- Where
- Brazil
- Volunteers
- 111 people
- Sponsor
- Laboratório Catarinense SA
Major Depressive Disorder
Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults
To evaluate the long-term safety and tolerability of flexible doses, 15 and 20 mg/day, of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01323478
- Testing
- Vortioxetine (Lu AA21004)
- Volunteers
- 71 people
- Sponsor
- H. Lundbeck A/S
Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder
The purpose of this research study is to investigate a closed-loop transcranial alternating current stimulation (tACS) device to evaluate its ability to reduce symptoms of major depressive disorder
- Trial name
- NCT07282678
- Testing
- Closed-loop tACS
- Where
- United States
- Volunteers
- 214 people
- Sponsor
- Pulvinar Neuro, LLC
Agitation in Adolescents and Young Adults With ASD
INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD
This is a Phase 2a, proof-of concept, 2-way, 2-period crossover, double-blind study to evaluate the safety and efficacy of INP105 as an acute treatment versus placebo in adolescents and young adults with autism spectrum disorder…
- Trial name
- CALM 201 (NCT05163717)
- Testing
- INP105
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Impel Pharmaceuticals
Epilepsy
WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01607333
- Testing
- Lamotrigine use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Overweight and Obesity, Body Weight Changes
Microalgae Extract Phaeosol Combined to Exercise in Healthy Overweight Women : Efficacy on Body Weight Management
PhaoeSOL (Microphyt, Baillargues, France) is a microalgae-based nutritional ingredient developed with a patented production process that has New Dietary Ingredient (NDI) status from the FDA (#1120).
- Conditions
- Overweight and Obesity, Body Weight Changes, Healthy Lifestyle, Exercise
- Trial name
- PHAEOSOL-ONE (NCT04761406)
- Testing
- Phaeosol group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Microphyt
Obesity
Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)
PrimaVie (Natreon Inc), is a a purified and standardized shilajit extract for nutraceutical use. Research indicates that PrimaVie® has targeted action for increasing energy, revitalization and anti-aging.
- Trial name
- NCT02026414
- Testing
- PrimaVie, Exercise
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Sanni Raju
Pulmonary Disease, Chronic Obstructive
TARA Working Prototype [Version 2]: Feasibility Study
TARA is a Digital Behaviour Change Intervention (DBCI) for Individuals with COPD (IwCOPD), which has been designed using a Human-Centred Design (HCD) methodology.
- Trial name
- NCT04320524
- Testing
- Technology-Assisted Respimat Adherence Digital Behaviour Change Intervention
- Sponsor
- Boehringer Ingelheim
Sleep Quality, Mood
A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing
This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy…
- Conditions
- Sleep Quality, Mood, Mental Clarity, Brain Fog
- Trial name
- NCT07721506
- Testing
- Edge+ease PM
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Edge+Ease
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.